The effect of differentiating and apoptotic agents on notch signalling pathway in hepatoblastoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Hepatoblastoma is a rare pediatric liver cancer with poorly understood molecular mechanisms.
• Notch signaling pathway plays a critical role in cell differentiation, proliferation, and development, but its role in hepatoblastoma remains unclear.

Purpose of the Study:

• To investigate the effect of various chemotherapeutic, differentiating, and apoptotic agents on Notch signaling pathway gene expression in hepatoblastoma.
• To explore the potential role of DNA methylation in regulating Notch pathway gene expression in this cancer.

Main Methods:

• HepG2 hepatoblastoma cell line was treated with cisplatin, doxorubicin, cytosin arabinoside, 13-cis-retinoic acid, 5-aza-2 -deoxycytidine, and arsenic trioxide.
• Gene expression profiling of 84 Notch signaling pathway genes was performed using Real Time PCR.
• Methylation-specific qPCR was used to assess the methylation status of selected genes exhibiting significant expression changes.

Main Results:

• Significant alterations in Notch signaling pathway gene expression were observed following treatment with chemotherapeutic agents, particularly cisplatin.
• High expression of genes associated with cell proliferation (e.g., HDAC1, NFKB1) and low expression of key Notch pathway components (e.g., NOTCH1, DLL1) were noted.
• DNA methylation was not found to be the primary driver of the observed gene expression changes.

Conclusions:

• Cisplatin significantly impacts gene expression within the Notch signaling pathway in hepatoblastoma.
• The findings suggest that Notch pathway dysregulation may contribute to hepatoblastoma pathogenesis.
• Further investigation into the therapeutic potential of agents affecting Notch signaling, excluding 5-aza-2 -deoxycytidine, is warranted.